Healthcare News

SUNNYVALE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of...

PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold® (migalastat) in...

IN8bio to Present at Upcoming Investor and Scientific Conferences in February

EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune...

WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...

Beghou Names Meredith Ressi President and Chief Growth Officer to optimize for client experience and success.

Byonyks’ FDA-cleared X1 advances home dialysis innovation, with Farrukh Usman leading a mission to transform patient-centric renal care globally.

- Los resultados clínicos y de seguridad del estudio de Fase 1 del VCN-01 (zabilugene almadenorepvec) en pacientes con retinoblastoma refractario se presentarán en una sesión con ponentes invitados en...

         This is the first trial combining Allarity’s stenoparib with another anti-cancer agent Stenoparib’s favorable safety profile supports potential for use in combination regimens Trial is fully...